New wearable sensor can quantifies itch


Itch torments its sufferers and can be as debilitating as chronic pain.

But it’s a hard symptom to measure – particularly for the 10 million U.S. children with atopic dermatitis, also known as eczema. They can’t always verbalize or quantify their suffering via a survey or scale.

It can also be difficult to objectively measure itch for adults with liver disease, kidney disease and certain cancers who experience its symptoms.

So, it’s hard to track how well treatments and drugs are working.

But now there is a soft, wearable sensor that actually quantifies itch by measuring scratching when placed on the hand developed by Northwestern University scientists. While it was tested in patients with atopic dermatitis, it can be used in any condition that causes itch.

The novel sensor can support clinical trials for new treatments, track treatment response and monitor for disease worsening—all in the home setting.

This is the first sensor able to capture all forms of scratching – finger, wrist and elbow motion related. It also is the first validated in a pediatric population where conditions like atopic dermatitis are the most common.

A new soft sensor developed by Northwestern University tracks and quantifies itch that torments millions of children with eczema. It will allow parents and doctors to monitor how well a treatment is working and early worsening of disease. It will also help drug companies measure the benefits of new therapies. Credit: Northwestern University

“Itch torments so many patients across so many conditions. It can be as debilitating as chronic pain,” said lead author Dr. Shuai “Steve” Xu, assistant professor of dermatology and of pediatrics at Northwestern University Feinberg School of Medicine. “If we’re able to quantify scratching accurately, then we have the ability to objectively quantify itching. This is really important in patients—like children—who can’t always verbalize or quantify their suffering.”

The paper will be published April 30 in Science Advances.

Xu also is an assistant professor of biomedical engineering at McCormick School of Engineering and Applied Science and medical director of the Querrey Simpson Institute for Bioelectronics, both at Northwestern.

About 10 million U.S. children have atopic dermatitis. The hallmark symptom is itch leading to sleep disturbance, poor neurocognitive development and, on average, a full night of sleep lost per week.

“Atopic dermatitis is so much more than just itchy skin,” Xu said. “It is a devastating disease that causes tremendous suffering worldwide. The quality of life of severe atopic dermatitis (not only for the child but also the parent) is equivalent to many life-threatening diseases.

“Patients with atopic dermatitis are 44% more likely to report suicidal thoughts as a result of the itch compared to controls. Thus, the ability to quantify their symptoms is really important to help new drugs get approved, but also support their day to day lives. In some ways—it’s like measuring glucose for diabetes…measuring itching in an atopic dermatitis patient may be just as important.”

“This is an exciting time for children and adults with atopic dermatitis—or eczema—because of the flurry of activity in developing new therapeutics,” said Dr. Amy Paller, chair of dermatology at Northwestern. “Nothing is more important to measure a medication’s effectiveness for eczema than itch, the symptom that both defines eczema and has the greatest impact on quality of life. This sensor could play a critical role in this regard, especially for children.”

In addition, clinicians and parents have the ability to track how well itch is being controlled in patients at home to monitor for treatment response, as well as early signs of worsening disease, Xu said.

This sensor marries advances in soft, flexible electronics that wrap seamlessly around the hand with machine learning algorithms that specifically identifies scratching without being tricked by similar motion-related movements (e.g. hand waving).

The sensor measures both low-frequency motion and high-frequency vibrations from the hand to significantly improve accuracy compared to wrist-watch tools.

The sensor was accepted into the Food and Drug Administration’s Drug Discovery Tool program. This program allows novel devices like this sensor to be qualified to aid in the approval of new drugs.

The study was conducted in two parts. The first part involved training the sensor to pick up scratching in healthy adults doing voluntary scratching behaviors. The second part tested the sensors on pediatric patients with atopic dermatitis. Parents set up an infrared camera to serve as the “gold standard”.

The algorithm and sensor were then used to count scratches in this pediatric patient population. More than 300 hours of sleep data was manually reviewed and scored for scratching and linked to the sensors.

Itching is the most frequent pathology in dermatology that has significant impacts on people’s mental health and social life. Transient receptor potential vanilloid 3 (TRPV3) channel is a promising target for treating pruritus. However, few selecetive and potent antagonists have been reported. This study was designed to identify selective TRPV3 antagonist and elucidate its anti‐pruritus pharmacology.

Experimental Approach

FlexStation and calcium fluorescence imaging were conducted to track the functional compounds. Whole‐cell patch clamp was used to record itch‐related ion channel currents. Homologous recombination and site‐directed mutagenesis were employed to construct TRPV3 channel chimeras and point mutations for exploring pharmacological mechanism. Mouse models were used for in vivo anti‐pruritus assay.

Key Results

An acridone alkaloid (citrusinine‐II) was purified and characterized from Atalantia monophylla. It directly interacts with Y564 within S4 helix of TRPV3 to selectively inhibit the channel with a half maximal inhibitory concentration (IC50) of 12.43 μM. Citrusinine‐II showed potential efficacy to attenuate both chronic and acute itch. Intradermal administration of citrusinine‐II (143 ng/skin site) nearly completely inhibited itch behaviours. It also shows significant analgesic effects. Little side effects of the compound are observed.

Conclusion and Implications

By acting as a selective and potent inhibitor of TRPV3 channel, citrusinine‐II shows valuable therapeutic effects in pruritus animal models and is a promising candidate drug and/or lead molecule for the development of anti‐pruritus drugs.

reference link :

More information: K.S. Chun at The University of Texas at Austin in Austin, TX el al., “A skin-conformable wireless sensor to objectively quantify symptoms of pruritus,” Science Advances (2021). … .1126/sciadv.abf9405


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.